WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients

Overview

Study to investigate the safety and efficacy of WAL 801 CL Dry Syrup on pruritus associated with paediatric atopic dermatitis in comparison with that of Ketotifen Fumarate Dry Syrup and to confirm the appropriateness of dosage of WAL801 Dry Syrup.

Full Title of Study: “Phase III Double-Blind Comparative Study of WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double
  • Study Primary Completion Date: January 2002

Interventions

  • Drug: WAL 801 CL Dry Syrup
  • Drug: Ketotifen Fumarate Dry Syrup
  • Drug: WAL 801 CL Dry Syrup placebo
  • Drug: Ketotifen Fumarate Dry Syrup placebo

Arms, Groups and Cohorts

  • Experimental: WAL 801 CL Dry Syrup + Placebo
  • Active Comparator: Ketotifen Fumarate Dry Syrup + Placebo

Clinical Trial Outcome Measures

Primary Measures

  • Degree of pruritus
    • Time Frame: at week 4

Secondary Measures

  • Degree of pruritus
    • Time Frame: at week 2
  • Degree of rash
    • Time Frame: at weeks 2 and 4
  • Pruritus score obtained through the itching questionnaire
    • Time Frame: at weeks 2 and 4
  • Impression on pruritus of the patient or the parent
    • Time Frame: at week 4
  • Occurrence of adverse events
    • Time Frame: up to 4 weeks
  • Number of patients with abnormal changes from baseline in laboratory measurements (hematological tests, blood biochemical tests, and urinalysis)
    • Time Frame: Baseline and week 4

Participating in This Clinical Trial

Inclusion Criteria

For inclusion in this study, patients must be pediatric atopic dermatitis patients that meet the following criteria and thus be appropriate for observation of pruritus. Diagnosis of atopic dermatitis was conducted in accordance with the "Definition and Diagnostic Criteria of Atopic Dermatitis" issued by the Japanese Dermatological Association.

  • 15 years of age or younger – Body weight of 14 kg or more – Outpatients – One week or longer has passed since the patient started to use an external steroid preparation at "Strong" or lower grade, or stopped using any external steroid preparation, at the time of obtainment of consent from the patient – Pruritus with "2" or higher grade, immediately before initial administration Exclusion Criteria:

  • Use of sustained release adrenocorticotropic hormone (Kenacort® A, Depo-medrol®, etc.), oral preparation of methotrexate, or oral preparation of ciclosporin, within 4 weeks before initial administration of the investigational product – Oral intake, inhalation and injection of any steroid within 2 weeks before initial administration of the investigational product – Use of any external steroid preparation at "Very Strong" or higher grade in any sites other than the face or scalp within 2 weeks before initial administration of the investigational product – Undergoing phototherapy – Undergoing specific desensitization therapy or modulation therapy – Past history of contact dermatitis caused by external steroid preparation – Possibility of exacerbation by an external steroid preparation of infectious skin disease caused by bacteria, fungi, or virus – Present and past history of convulsive disorder, such as epilepsy (convulsion threshold values may be lowered by the reference drug, Ketotifen Fumarate) – Clinically significant hepatic, renal, or cardiac disease or other complications: therefore, judgement that the patient is ineligible for inclusion in this study (Please note that patients must be excluded from the study if the patients fell under Grade 2 or more, in the MHW (Ministry of health and welfare) Adverse Reaction Severity Classification Criteria.) – Past history of allergy to any drug – Participation in any other clinical study, or history of participation in any other clinical study within 6 months before the date when the patient gave consent to participate in this study – Judgement by the Principal Investigator or Investigator that the patient is ineligible for inclusion in this study

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 15 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Boehringer Ingelheim
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.